Image Place holder

Bruna Pellini, MD

Specialty: Medical Oncology
Sub Specialty: Medical Oncology
Program: Thoracic Oncology

Overview

Cancer Focus: Lung Cancer, Mesothelioma, Pancoast Tumor, Thymoma

Dr. Bruna Pellini is an Assistant Member at the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and an Assistant Professor at Morsani College of Medicine at University of South Florida. She received her medical degree from the Universidade Federal do Rio Grande do Sul, Brazil, and completed her residency at University of Central Florida College of Medicine, where she was awarded the “Clinical Skills Award” in 2015 and was inducted into the prestigious Alpha Omega Alpha Honor Medical Society in 2016. Dr. Pellini completed her medical oncology fellowship at Washington University School of Medicine, St. Louis, where she worked at the laboratory of Aadel Chaudhuri, MD, Ph.D. researching circulating tumor DNA for molecular residual disease detection across different solid tumors. Dr. Pellini is an active member of the Lung Cancer Center of Excellence and the Molecular Medicine Committees at Moffitt Cancer Center. She specializes in the care of patients diagnosed with lung cancer. Her research interest lies in the development of clinical trials with novel therapeutics targeting genomic alterations in non-small cell lung cancer, to study liquid biopsies as a biomarker to monitor treatment response and molecular residual disease, and to study the genomic and transcriptomic landscape of lung cancer in patients of Hispanic ancestry.    


Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • Washington University School of Medicine - Medical Oncology

Residency:

  • University of Central Florida College of Medicine - Internal Medicine

Medical School:

  • Universidade Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina, Brazil
Participating Trials

CLINICAL TRIAL 20373
TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. Am Soc Clin Oncol Educ Book. 2021 Mar.41:1-23. Pubmedid: 33979196.
  • Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN. A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. J Thorac Dis. 2021 Jul.13(7):4054-4062. Pubmedid: 34422335. Pmcid: PMC8339787.
  • Pellini B, Pejovic N, Feng W, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Petty M, Jiang Y, Singh A, Maher CA, Henke LE, Park H, Ciorba MA, Kim H, Mutch MG, Pedersen KS, Tan BR, Hawkins WG, Fields RC, Chaudhuri AA. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precis Oncol. 2021 Feb.5. Pubmedid: 34250420. Pmcid: PMC8232837.
  • Pellini B, Szymanski J, Chin RI, Jones PA, Chaudhuri AA. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Thorac Surg Clin. 2020 May.30(2):165-177. Pubmedid: 32327175.
  • Chaudhuri AA, Pellini B, Pejovic N, Chauhan PS, Harris PK, Szymanski JJ, Smith ZL, Arora VK. Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. JCO Precis Oncol. 2020 Jul.4. Pubmedid: 32923907. Pmcid: PMC7448529.
  • Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I. The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. Am J Transplant. 2020 Feb.20(2):589-592. Pubmedid: 31446673.
  • Pellini Ferreira B, Vasquez J, Carilli A. Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide. Am J Med Sci. 2017 Jun.353(6):610-612. Pubmedid: 28641727.
  • Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP. Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. Laryngoscope. 2017 Jul.127(7):1583-1588. Pubmedid: 27905113.
  • Uchôa Dde M, Graudenz MS, Callegari-Jacques SM, Hartmann CR, Ferreira BP, Fitarelli-Kiehl M, Edelweiss MI. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors. Pathol Res Pract. 2014 Jul.210(7):432-439. Pubmedid: 24726267.
  • Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors. 2012 Oct.4(4):e55. Pubmedid: 23372919. Pmcid: PMC3557569.

Patient Comments
Overall Satisfaction
4.9

63 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments